The global clinical chemistry analyzers market accounted for USD 16 billion in 2021 and is expected to grow at a CAGR of 4.7% from 2022 to 2029. The increasing prevalence of chronic diseases, such as diabetes, is predicted to be one of the high impact rendering drivers of this market. This subsequent increase in disease prevalence has triggered companies to produce advanced analyzers at a large scale, to aid in diagnosis. Consequently, the high need for chemistry analyzers led to unprecedented growth in new market entrants, resulting in high competition.
The technological innovations in clinical chemistry analyzers have led to early disease detection and specialized diagnosis in the areas of oncology, gynecology, & endocrinology and enabled testing on a larger scale. The advancements comprise advanced modeling & parameter estimation, better resolution, improved pattern recognition, computer-assisted interpretation, and artificial intelligence.
U.S. clinical chemistry analyzers market, by test, 2017 - 2029 (USD Million)
The benefits of the above-mentioned advancements and automated analyzers are automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment. These tools also offer analysis of a wide range of samples and facilitate immediate generation of results, reflecting their potential applications in the intensive care unit, outpatient clinics, and emergency as well as surgical wards in the future. These benefits are estimated to drive physician preference for these analyzers, thus creating high potential opportunities for growth during the forecast period.
Reagents accounted for the largest share in the product segment in 2015. The substantial share is predicted to be a consequence of a wide array of reagents present in the market, catering to different requirements of clinicians. These reagents predominantly include enzymes, substrates, specific proteins, electrolytes, lipids, and others, which are imperative to obtain accurate results in analytical procedures.
In addition, reagents are believed to be highly cost-efficient, possess optimum sensitivity, linearity, and precision, which thereby, ensures minimized performance variation. The aforementioned benefits are predicted to be highly responsible for encouraging clinicians to use reagents for accurate diagnosis.
Global clinical chemistry analyzers market share, by product, 2016
Basic MetabolicPanel (BMP) held a dominant share of the test segment in 2015, as a consequence of growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities. Rising importance of and awareness regarding point-of-care testing is also one of the key contributing factors toward the segment share. BMP comprises a set of tests that provide clinical information pertaining to problems caused by a chemical imbalance in the body to the medical examiners.
The associated benefits with this test have resulted in the high acceptance of the same, thereby widening the segment share over the years. Moreover, BMP is increasingly being used and accepted in a wide array of applications, such as in newborn screening, which facilitates early detection of congenital genetic as well as metabolic disorders. According to a research paper published in NCBI, it possesses the ability to detect 30 inherited metabolic disorders in a single dried filter paper blood spot.
Hospitals dominated the end-use segment in 2016, owing to the high patient volume, frequent readmissions, and large sample volumes. Moreover, supportive infrastructure facilitates successful diagnostic procedures, thus, resulting in a higher share of hospitals. The increasing number of government initiatives aimed at promoting efficient diagnostic facilities to generate quick results and improve overall efficiency also serves as key contributing factors to the substantial share of the segment.
In addition, in the current scenario, hospitals are increasingly inclined toward acquiring fully automated systems with built-in quality-assurance capabilities, possessing the ability to process a large number of samples. These factors are estimated to exert positive influence on segment growth.
In 2016, North America held the substantial share of the clinical chemistry analyzers market. The supportive government initiatives and high implementation of practice guidelines released by healthcare organizations present across this region are some of the key factors responsible for the high share registered by this region.
Due to increase in outsourcing of manufacture of these analyzers to Asia Pacific countries, such as India and China, this region is anticipated to grow at an exponential rate during the forecast period. Furthermore, high R&D investment by the global players and presence of unexplored opportunities in this region serve as high growth rendering drivers.
Some of the key market participants are F.Hoffmann La Roche; Thermo Fisher Scientific, Inc.; Johnson & Johnson; and Siemens AG. The aforementioned companies are extensively undertaking new and advanced product development activities, collaborative strategies, and mergers & acquisitions, leading to significant growth in this sector.
For instance, in January 2017, Roche launched cobas m 511, integrated hematology analyzer. This product was made available in many countries following the European approval system (CE mark). This product was launched to expand its hematology testing capabilities.
In March 2023, world scientific leader Thermo Fisher Scientific Inc. announced the completion of acquiring “The Binding Site Group”, the world's leading specialty diagnostics company. Binding Site expands the existing portfolio of specialty diagnostics by adding groundbreaking innovations in diagnostics and multiple myeloma surveillance.
In October 2022, Roche launched the PRAME (EPR20330) antibody to detect PRAME protein expression in patients who may have melanoma. Understanding PRAME protein expression will help make more informed clinical decisions and may improve patient outcomes.
Report Attribute |
Details |
Market size value in 2021 |
USD 16 billion |
Revenue forecast in 2029 |
USD 19.23 billion |
Growth Rate |
CAGR of 4.7% from 2022 to 2029 |
Base year for estimation |
2021 |
Historical data |
2017 - 2020 |
Forecast period |
2022 - 2029 |
Quantitative units |
Revenue in USD billion and CAGR from 2022 to 2029 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segment Scope |
Product, test, end-use, region |
Region scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; Japan; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
F.Hoffmann La Roche; Thermo Fisher Scientific, Inc.; Johnson & Johnson; Siemens AG |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2029. For the purpose of this study, Grand View Research has segmented the global clinical chemistry analyzers market on the basis of product, test, end-use, and region:
Product Outlook (Revenue, USD Million, 2017 - 2029)
Analyzers
Small
Medium
Large
Very Large
Reagents
Calibrators
Controls
Standards
Others
Others
Test Outlook (Revenue, USD Million, 2017 - 2029)
Basic Metabolic Panel
Electrolyte Panel
Liver Panel
Lipid Profile
Renal Profile
Thyroid Function Panel
Specialty Chemical Tests
End-use Outlook (Revenue, USD Million, 2017 - 2029)
Hospitals
Academic Research Centers
Diagnostic Laboratories
Others
Regional Outlook (Revenue, USD Million, 2017 - 2029)
North America
The U.S
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.